Sep 17, 2021; Symposium
IMI RHAPSODY Final Symposium
Andreas Festa - Eli Lilly, diabetologist
Elizabeth Robertson - Diabetes UK, patient advocate
Claire Varin - RHAPSODY industry coordinator, Servier Paris
Emma Ahlqvist - Lund University Diabetes Centre
Roderick Slieker - Leiden University Medical Center
Steven Kahn - University of Washington, RHAPSODY scientific advisor
By defining novel biomarkers for an improved taxonomy of type 2 diabetes and its progression, RHAPSODY intends to open up new roads towards diabetes prevention and treatment, and accelerate the development of personalised diabetes care.
In the end of the project, the RHAPSODY team is eager to share its achievements with patient and healthcare communities and welcomes all to a half-day symposium on September 17, 2021.
13.30h
ONLINE RECEPTION
14.00h
Welcome
Bernard Thorens
14.05h
Diabetes care – a clinician`s point of view
Andreas Festa
14.20h
Diabetes care - a patient's perspective - Laying the foundations for targeted prevention and treatments for people living with type2 diabetes and those at risk
Elizabeth Robertson
14.35h
What does the Innovative Medicines Initiative do to help patients with diabetes?
Claire Varin
14.45h
The RHAPSODY project: Biomarkers in type 2 diabetes
Bernard Thorens
15.15h
BREAK
15.45
A new diabetes patient sub-classification: what's next?
Emma Ahlqvist
16.00h
A new diabetes patient sub-classification: its application in RHAPSODY
Roderick Slieker
16.15h
Panel discussion
"Why does it matter?"
Moderator: Andreas Festa
Participants: Claire Varin, Bernard Thorens, Emma Ahlqvist, Elizabeth Robertson, Steven Kahn
17.15h
Wrap-up, conclusions and open discussion
Claire Varin,
Bernard Thorens
17.30h
END OF THE MEETING